Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine

BACKGROUND. Patients with previously untreated BRAF V600E mutation-positive melanoma in BREAK-3 showed a median overall survival (OS) of 18.2 months for dabrafenib versus 15.6 months for dacarbazine (hazard ratio [HR], 0.76; 95% confidence interval, 0.48–1.21). Because patients receiving dacarbazine...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Latimer, Nicholas R., Abrams, Keith R., Amonkar, Mayur M., Stapelkamp, Ceilidh, Swann, R. Suzanne
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2015
Teme:
Melanoma and Cutaneous Malignancies
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492231/
https://ncbi.nlm.nih.gov/pubmed/26040620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0429
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki